## LH: Labcorp Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($253.99)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. What Labcorp Holdings (LH)'s Slowing Growth and Margin Pressure Means For Shareholders**
- Source: Simply Wall Street | 20251211T030826 | Neutral | Relevance: 98%
-  Labcorp Holdings (LH) is facing concerns due to persistently slow organic sales growth, declining adjusted operating margins, and a weaker return on invested capital. The company's investment narrative highlights the need to stabilize profitability in its core businesses and the emergence of structural profitability issues as key risks. Despite these challenges, Labcorp's expanded precision oncology and digital pathology efforts offer potential offsets to slower organic growth and could aid in margin recovery.

**2. Rep. April McClain Delaney Purchases Shares of Labcorp Holdings Inc. (NYSE:LH)**
- Source: MarketBeat | 20251210T071606 | Somewhat-Bullish | Relevance: 98%
-  Representative April McClain Delaney of Maryland recently purchased shares of Labcorp Holdings Inc. (NYSE:LH) between $1,001 and $15,000 on November 17, 2025. This transaction comes as Labcorp reported strong quarterly earnings, beating EPS estimates and achieving significant revenue growth. The company also declared a quarterly dividend of $0.72 per share, and institutional investors have been actively adjusting their positions in the stock.

**3. Amundi Sells 799,075 Shares of Labcorp Holdings Inc. $LH**
- Source: MarketBeat | 20251209T120838 | Neutral | Relevance: 98%
-  Amundi significantly reduced its stake in Labcorp Holdings Inc. (NYSE:LH) by selling 799,075 shares, lowering its holdings to 274,307 shares. Despite this large sale, Wall Street maintains a "Moderate Buy" consensus rating for Labcorp with an average target price of $297.07, following a quarter where Labcorp exceeded EPS estimates and announced a quarterly dividend. Insider selling by Director Richelle P. Parham and CEO Adam H. Schechter was also noted.

**4. 2Xideas AG Has $7.33 Million Holdings in Labcorp Holdings Inc. $LH**
- Source: MarketBeat | 20251209T082531 | Neutral | Relevance: 98%
-  2Xideas AG significantly reduced its stake in Labcorp Holdings Inc. (NYSE:LH) by 14.0% in the second quarter, bringing its total holdings to $7.33 million. Despite this, other institutional investors have recently shown increased interest in Labcorp shares, even as some analysts have adjusted price targets and ratings. The medical research company recently reported strong quarterly earnings, beating consensus estimates, and declared a quarterly dividend.

**5. What Labcorp Holdings (LH)'s Slowing Growth and Margin Pressure Means For Shareholders**
- Source: Simply Wall Street | 20251211T032445 | Neutral | Relevance: 98%
-  Labcorp Holdings is facing challenges including persistently slow organic sales growth, declining adjusted operating margins, and a weaker return on invested capital. The company may need to reassess its cost structure and capital allocation strategies to address investor concerns about its profitability and growth opportunities. Despite these issues, Labcorp's ventures into precision oncology and digital pathology, including new ctDNA tests and AI collaborations, are seen as potential avenues for higher-value growth that could offset slower organic performance and aid margin recovery.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($3.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.7%)
- Blackrock Inc.: 9.8% (-10.3%)
- State Street Corpora: 4.6% (-0.8%)
- Victory Capital Mana: 3.2% (+20.0%)
- JPMORGAN CHASE & CO: 2.6% (+64.8%)

### Key Risks

1. Insider selling cluster: $3.4M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +4.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Forward P/E 15.1x stretched relative to 7% growth. Insider selling cluster ($3.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.0B |
| Beta | 0.96 |
| 52W Range | $209.38 - $293.72 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 15.1 |
| Current P/E | 16.2 |
| YoY Growth | 7.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -4.3% to 0.1% (+4.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 at 1.6% confirms short-term momentum alignment. RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.13% (CS: 40) | Neutral |
| RSI_14 | 50.8 | Neutral |
| MACD Histogram | 0.01 | Bullish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 0.988x | Below |
| vs SMA200 | 1.029x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $264.73
- **Stop Loss:** $253.99 (4.1% risk)
- **Target:** $275.47 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 128
- **Position Value:** $33,885.44
- **Portfolio %:** 33.89%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-05 (Est: $3.94)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.14 | $4.18 | +1.0% |
| 2025Q2 | $4.18 | $4.35 | +4.1% |
| 2025Q1 | $3.73 | $3.84 | +2.8% |
| 2024Q4 | $3.39 | $3.45 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*